Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model-Reference-Cited by-同舟云学术

Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model

Published:2020-04-21 Issue:5 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Patel Anasuya¹,Sangle Ganesh V.²,Trivedi Jinal¹,Shengule Sushant A.²,Thorve Deepak¹,Patil Mohan²,Deshmukh Nitin J.²,Choudhari Bhushan¹,Karade Avinash¹,Gupta Sangita¹,Bhagwat Sachin¹,Patel Mahesh¹

Affiliation:

1. New Drug Discovery, Wockhardt Research Centre, Aurangabad, Maharashtra, India

2. Diabetes Research Lab, New Drug Discovery, Wockhardt Research Centre, Aurangabad, Maharashtra, India

Abstract

Fluoroquinolones are reported to possess immunomodulatory activity; hence, a novel benzoquinolizine fluoroquinolone, levonadifloxacin, was evaluated in lipopolysaccharide-stimulated human whole-blood (HWB) and mouse acute lung injury (ALI) models. Levonadifloxacin significantly mitigated the inflammatory responses in an HWB assay through inhibition of proinflammatory cytokines and in the ALI model by lowering lung total white blood cell count, myeloperoxidase, and cytokine levels. The immunomodulatory effect of levonadifloxacin, along with promising antibacterial activity, is expected to provide clinical benefits in the treatment of infections.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00084-20

Reference25 articles.

1. In Vitro Activity of the New Quinolone WCK 771 against Staphylococci

2. Activity of the new quinolone WCK 771 against pneumococci

3. Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models

4. In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms

5. In Vitro Activity of the Quinolone WCK 771 against Recent U.S. Hospital and Community-Acquired Staphylococcus aureus Pathogens with Various Resistance Types

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of CAV and CAVIN Family Genes in Acute Lung Injury based on DeepGENE;Current Gene Therapy;2023-02

2. Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin;Critical Care Research and Practice;2022-09-09

3. Potential new fluoroquinolone treatments for suspected bacterial keratitis;BMJ Open Ophthalmology;2022-07

4. Chemistry, Biological Properties and Analytical Methods of Levonadifloxacin: A Review;Critical Reviews in Analytical Chemistry;2020-12-13

5. A Comparative Assessment of Clinical, Pharmacological and Antimicrobial Profile of Novel Anti-methicillin-resistant Staphylococcus aureus Agent Levonadifloxacin: Therapeutic Role in Nosocomial and Community Infections;Indian Journal of Medical Microbiology;2019-10